4D Molecular Therapeutics, Inc. (FDMT)
NASDAQ: FDMT · Real-Time Price · USD
10.23
-0.49 (-4.57%)
Nov 20, 2026, 4:00 PM EST - Market closed
4D Molecular Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 39.1 | 60.24 | 149.34 | 249.11 | 52.35 | 153 |
Short-Term Investments | 267.89 | 342.41 | 275.54 | 39.12 | 161.2 | 94.78 |
Cash & Short-Term Investments | 306.99 | 402.66 | 424.88 | 288.23 | 213.55 | 247.78 |
Cash Growth | 0.63% | -5.23% | 47.41% | 34.97% | -13.81% | -10.46% |
Accounts Receivable | - | - | - | - | - | 0.05 |
Other Receivables | 4.02 | - | - | - | - | 0.7 |
Receivables | 4.02 | - | - | - | - | 0.75 |
Prepaid Expenses | 11.28 | 10.48 | 10.06 | 8.36 | 6.96 | 7.76 |
Total Current Assets | 322.29 | 413.13 | 434.93 | 296.59 | 220.51 | 256.28 |
Property, Plant & Equipment | 26.98 | 33.01 | 40.61 | 31.67 | 35.35 | 28.95 |
Long-Term Investments | 68.04 | 111.38 | 80.58 | 10.95 | 4.91 | 67.65 |
Other Long-Term Assets | 11.44 | 9.19 | 4.26 | 0.68 | 1.08 | 0.6 |
Total Assets | 428.75 | 566.71 | 560.38 | 339.89 | 261.85 | 353.49 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 7.88 | 11.16 | 4.39 | 3.52 | 3.32 | 4.76 |
Accrued Expenses | 35.21 | 26.87 | 18.87 | 12.01 | 8.87 | 7.74 |
Current Portion of Leases | 5.31 | 5.59 | 5.64 | 3.15 | 2.66 | 1.23 |
Current Unearned Revenue | 3.99 | 0.36 | 0.26 | 0.27 | 0.88 | 2.6 |
Total Current Liabilities | 52.39 | 43.99 | 29.15 | 18.95 | 15.73 | 16.34 |
Long-Term Leases | 13.42 | 15.82 | 18.97 | 11.52 | 13.47 | 15.22 |
Long-Term Unearned Revenue | 2.83 | 0.75 | 1.06 | 0.97 | 1.08 | 2.49 |
Other Long-Term Liabilities | 2.48 | 0.5 | 0.6 | 0.62 | 0.23 | 0.33 |
Total Liabilities | 90.81 | 61.05 | 49.78 | 32.06 | 30.51 | 34.38 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.01 | 0.01 | 0.01 | 0 | 0 | 0 |
Additional Paid-In Capital | 1,275 | 1,221 | 1,087 | 723.14 | 547.02 | 526.52 |
Retained Earnings | -936.06 | -716.3 | -576.2 | -415.33 | -314.49 | -207 |
Comprehensive Income & Other | -1.01 | 0.73 | 0.23 | 0.02 | -1.2 | -0.42 |
Total Common Equity | 337.94 | 505.66 | 510.61 | 307.83 | 231.34 | 319.11 |
Shareholders' Equity | 337.94 | 505.66 | 510.61 | 307.83 | 231.34 | 319.11 |
Total Liabilities & Equity | 428.75 | 566.71 | 560.38 | 339.89 | 261.85 | 353.49 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 38.41 | 21.41 | 24.61 | 14.67 | 16.12 | 16.45 |
Net Cash (Debt) | 336.62 | 492.62 | 480.85 | 284.52 | 202.34 | 298.98 |
Net Cash Growth | -3.81% | 2.45% | 69.01% | 40.61% | -32.32% | 8.04% |
Net Cash Per Share | 4.90 | 8.50 | 8.91 | 7.27 | 6.25 | 10.78 |
Filing Date Shares Outstanding | 56.38 | 51.05 | 46.3 | 49.78 | 33.23 | 32.24 |
Total Common Shares Outstanding | 56.37 | 57.61 | 45.79 | 43.08 | 32.63 | 32.22 |
Working Capital | 269.89 | 369.15 | 405.78 | 277.64 | 204.78 | 239.94 |
Book Value Per Share | 5.99 | 8.78 | 11.15 | 7.15 | 7.09 | 9.90 |
Tangible Book Value | 337.94 | 505.66 | 510.61 | 307.83 | 231.34 | 319.11 |
Tangible Book Value Per Share | 5.99 | 8.78 | 11.15 | 7.15 | 7.09 | 9.90 |
Machinery | 17.1 | 17.68 | 17.17 | 14.61 | 12.61 | 7.12 |
Construction In Progress | - | - | 1.18 | 0.55 | 0.48 | 10.07 |
Leasehold Improvements | 18.47 | 18.47 | 17.76 | 16.9 | 16.9 | 2.53 |